• Publications
  • Influence

Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage your publications. Semantic Scholar automatically creates author pages based on data aggregated from public sources and our publisher partners.
  • Eiichi Araki, Yukiko Onishi, +4 authors Toshitaka Yajima
  • Medicine
  • Journal of diabetes investigation
  • 2016 (First Publication: 22 January 2016)
  • Abstract Introduction Dapagliflozin treatment when added to insulin therapy in Japanese patients with type 2 diabetes remains to be evaluated. Materials and Methods This was a multicenter,Expand
  • Yu Nakamura, Yukimichi Imai, +6 authors Akira Homma
  • Medicine
  • Dementia and Geriatric Cognitive Disorders Extra
  • 2011 (First Publication: 24 June 2011)
  • Background: As of 2010, the rivastigmine patch was licensed for the treatment of Alzheimer’s disease (AD) in 64 countries. Methods: This 24-week, multicenter, randomized, double-blind,Expand
  • Eiichi Araki, Yukiko Onishi, Michiko Asano, Hyosung Kim, Toshitaka Yajima
  • Medicine
  • Diabetes, obesity & metabolism
  • 2017 (First Publication: 1 April 2017)
  • AIMS To evaluate the efficacy and safety of dapagliflozin as add-on to insulin in Japanese patients with type 2 diabetes. MATERIALS AND METHODS Insulin-treated Japanese patients were randomized toExpand
  • Hirotaka Watada, Masanari Shiramoto, +7 authors Eiichi Araki
  • Medicine
  • Diabetes, obesity & metabolism
  • 2018 (First Publication: 21 December 2018)
  • Aims To assess the pharmacokinetics/pharmacodynamics (PK/PD) of dapagliflozin, a sodium‐glucose co‐transporter 2 inhibitor that increases urinary glucose excretion (UGE) and its major metabolite,Expand
  • Hitoshi Shimada, Catarina Nilsson, Yoshinori Noda, Hyosung Kim, Torbjörn Lundström, Toshitaka Yajima
  • Medicine
  • Journal of atherosclerosis and thrombosis
  • 2017 (First Publication: 24 March 2017)
  • Aims: Omega-3-carboxylic acids (OM3-CA) contain omega-3 free fatty acids, such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), as carboxylic acids. Food intake is known to affect theExpand
  • Eiichi Araki, Hirotaka Watada, +9 authors Anna Maria Langkilde
  • Medicine
  • Diabetes, obesity & metabolism
  • 2019 (First Publication: 19 November 2019)
  • Abstract Aims To investigate the safety and tolerability of 5 and 10 mg dapagliflozin added to insulin therapy over 52 weeks in Japanese patients with inadequately controlled type 1 diabetes mellitusExpand
  • Koutaro Yokote, Kiyoshi Niwa, +7 authors Toshitaka Yajima
  • Medicine
  • Circulation journal : official journal of the…
  • 2020 (First Publication: 11 April 2020)
  • BACKGROUND This study is the first to evaluate the short-term efficacy and long-term safety of AZD0585, a mixture of omega-3 free fatty acids, in Japanese patients with dyslipidemia.Methods andExpand
  • Yoshinori Noda, Catarina Nilsson, Hitoshi Shimada, Hyosung Kim, Torbjörn Lundström, Toshitaka Yajima
  • Medicine
  • Clinical pharmacology in drug development
  • 2018 (First Publication: 1 February 2018)
  • OM3-CA (omega-3-carboxylic acids) is a complex mixture of omega-3 carboxylic acids, particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which is approved in the United States forExpand